Leiden University Medical Center
Leiden's university hospital, a cradle of therapeutic cancer vaccines and tumour immunology and the base for the Dutch TME rectal cancer trial.
The LUMC's tumour immunology tradition runs from Cornelis Melief's synthetic long peptide HPV16 vaccine, developed with ISA Pharmaceuticals, to the immunology groups of Sjoerd van der Burg and Ferry Ossendorp, and Ton Schumacher and John Haanen of the Netherlands Cancer Institute hold Leiden professorships. Cornelis van de Velde's Dutch TME trial established total mesorectal excision with short-course radiotherapy as the standard for rectal cancer, and Judith Bovée's pathology group is a world reference for bone and soft tissue tumours. Leiden co-owns the Holland Proton Therapy Centre and runs a large haematology and transplant programme. The Leiden Oncology Center coordinates care with regional hospitals.
- Therapeutic cancer vaccines
- Tumour immunology
- Rectal cancer surgery and radiotherapy
- Bone and soft tissue tumour pathology
- HollandPTC
Immunologist who showed T cells recognise cancer neoantigens, the basis for personalised vaccines and TCR therapies.
John Haanen led the first randomised phase 3 trial of TIL therapy, which beat ipilimumab in melanoma.
Pages like this
not linked directly; found by shared links- Key paperNICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients
Shares Ton Schumacher, John Haanen, Netherlands Cancer Institute (NKI-AvL), Immune checkpoint inhibitors.
- Key paperRohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma
Shares Ton Schumacher, John Haanen, Netherlands Cancer Institute (NKI-AvL), Melanoma.
- InstitutionMaria Skłodowska-Curie National Research Institute of Oncology
Shares Proton therapy, Sarcomas (soft tissue, bone, GIST), Melanoma, Immune checkpoint inhibitors.
- CompanyNouscom
Shares Off-the-shelf cancer vaccines, Neoantigen, Colorectal cancer.
- IdeaSelect patients for cell therapy by whether their tumour holds reactive T cells
Shares Ton Schumacher, John Haanen, Melanoma.
- PersonTimothy A. Chan
Shares Neoantigen, Melanoma, Immune checkpoint inhibitors.
- Key paperNADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma
Shares John Haanen, Netherlands Cancer Institute (NKI-AvL), Melanoma, Immune checkpoint inhibitors.
- Key paperNICHE-2: a single dose of ipilimumab and two of nivolumab before surgery clears dMMR colon cancer in most patients
Shares Ton Schumacher, Netherlands Cancer Institute (NKI-AvL), Immune checkpoint inhibitors, Colorectal cancer.